Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL
NCT04659434
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
51
Enrollment
OTHER
Sponsor class
Conditions
Diffuse Large B Cell Lymphoma
Relapsed Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Interventions
DRUG:
Sintilimab
Sponsor
Qian Wenbin